These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials. Tepper SJ; Ashina M; Reuter U; Hallström Y; Broessner G; Bonner JH; Picard H; Cheng S; Chou DE; Zhang F; Klatt J; Mikol DD J Headache Pain; 2021 Jul; 22(1):81. PubMed ID: 34301173 [TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine. Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Cheng S; Numachi Y; Peng C; Xue F; Mikol DD Headache; 2021 Apr; 61(4):653-661. PubMed ID: 33764538 [TBL] [Abstract][Full Text] [Related]
7. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults. Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Lenz R; Wang Y; Cheng S; Hirama T; Mikol DD Headache; 2019 Nov; 59(10):1731-1742. PubMed ID: 31612482 [TBL] [Abstract][Full Text] [Related]
8. A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study. Yu S; Kim BK; Wang H; Zhou J; Wan Q; Yu T; Lian Y; Arkuszewski M; Ecochard L; Wen S; Yin F; Li Z; Su W; Wang SJ J Headache Pain; 2022 Nov; 23(1):146. PubMed ID: 36404301 [TBL] [Abstract][Full Text] [Related]
9. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study. Takeshima T; Sakai F; Hirata K; Imai N; Matsumori Y; Yoshida R; Peng C; Cheng S; Mikol DD Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117 [TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis. Ashina M; Tepper SJ; Brandes JL; Reuter U; Boudreau GP; Weatherall M; Gantenbein AR; Doležil D; Klatt J; Wang A; Karanam AK; Cheng S; Mikol DD Headache; 2022 May; 62(5):624-633. PubMed ID: 35593783 [TBL] [Abstract][Full Text] [Related]
11. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study. Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F; Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862 [TBL] [Abstract][Full Text] [Related]
12. Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial. Hirata K; Takeshima T; Sakai F; Numachi Y; Yoshida R; Koukakis R; Hasebe M; Yui D; da Silva Lima GP; Cheng S BMJ Open; 2023 Aug; 13(8):e068616. PubMed ID: 37597868 [TBL] [Abstract][Full Text] [Related]
13. Erenumab versus topiramate: post hoc efficacy analysis from the HER-MES study. Ehrlich M; Hentschke C; Sieder C; Maier-Peuschel M; Reuter U J Headache Pain; 2022 Nov; 23(1):141. PubMed ID: 36380284 [TBL] [Abstract][Full Text] [Related]
14. Erenumab (AMG 334) in episodic migraine: Interim analysis of an ongoing open-label study. Ashina M; Dodick D; Goadsby PJ; Reuter U; Silberstein S; Zhang F; Gage JR; Cheng S; Mikol DD; Lenz RA Neurology; 2017 Sep; 89(12):1237-1243. PubMed ID: 28835404 [TBL] [Abstract][Full Text] [Related]
15. A Controlled Trial of Erenumab for Episodic Migraine. Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Sapra S; Picard H; Mikol DD; Lenz RA N Engl J Med; 2017 Nov; 377(22):2123-2132. PubMed ID: 29171821 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of Erenumab for Migraine Prevention in Japanese Patients with Episodic and Chronic Migraine: Results of a Post-Hoc Pooled Analysis. Kitamura S; Takeshima T; Yui D; da Silva Lima GP; Koukakis R; Peng C; Yoshida R; Numachi Y; Hasebe M Neurol Ther; 2023 Dec; 12(6):1993-2006. PubMed ID: 37698837 [TBL] [Abstract][Full Text] [Related]
17. Real-World Patient Experience With Erenumab for the Preventive Treatment of Migraine. Robblee J; Devick KL; Mendez N; Potter J; Slonaker J; Starling AJ Headache; 2020 Oct; 60(9):2014-2025. PubMed ID: 32920850 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study. Reuter U; Goadsby PJ; Ferrari MD; Da Silva Lima GP; Mondal S; Kalim J; Hasan F; Wen S; Arkuszewski M; Pandhi S; Stites T; Lanteri-Minet M Neurology; 2024 May; 102(10):e209349. PubMed ID: 38669638 [TBL] [Abstract][Full Text] [Related]
19. Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials. Ashina M; Goadsby PJ; Dodick DW; Tepper SJ; Xue F; Zhang F; Brennan F; Paiva da Silva Lima G JAMA Neurol; 2022 Feb; 79(2):159-168. PubMed ID: 34928306 [TBL] [Abstract][Full Text] [Related]
20. Does MIDAS reduction at 3 months predict the outcome of erenumab treatment? A real-world, open-label trial. De Icco R; Vaghi G; Allena M; Ghiotto N; Guaschino E; Martinelli D; Ahmad L; Corrado M; Bighiani F; Tanganelli F; Bottiroli S; Cammarota F; Sances G; Tassorelli C J Headache Pain; 2022 Sep; 23(1):123. PubMed ID: 36115947 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]